FDA What's New: Drugs · 6/15/2026
FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
FDA is concerned about telehealth companies promoting compounded drugs, including glucagon-like peptide-1 receptor agonists (GLP-1s) and other drugs, with false or misleading claims.
Why this is tracked
This item matched GLP-1, Medicare, Part D, CMS, FDA, coverage, pricing, prior authorization, or access terms used by the daily monitor.
Read the source
This page summarizes and links to the original source. Use the source article, CMS/FDA notices, plan documents, and clinician guidance for decisions.